Bisoprolol tab p / 10 mg film about 50 pieces of ozone

Description

Composition
Active substance:
1 tablet contains 2.5 mg: 2.5 mg bisoprolol fumarate. 1 tablet contains 5.0 mg: 5.0 mg bisoprolol fumarate. 10.0 mg 1 tablet contains: 10.0 mg bisoprolol fumarate.
Product form:
Tablets, film-coated 2.5 mg, 5 mg and 10 mg. 10, 25, 30, 50 tablets in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50, 60 or 100 tablets per plastic jars for medicaments. One jar or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
Contraindications
– Increased sensitivity to bisoprolol, other components of the drug to other beta-blockers, – acute heart failure or heart failure decompensation requiring holding inotropic therapy – shock (including cardiogenic) – pulmonary edema – atrioventricular (AV) blockade II-III extent without the pacemaker, – sinoatrial block, – sick sinus syndrome, – bradycardia (heart rate less than 60 beats / min.)., – severe hypotension (systolic blood pressure (BP) 100 mm Hg.). – heavy f rmy bronchial asthma and chronic obstructive pulmonary disease (COPD) in history, – expressed peripheral circulatory disorders, Raynaud’s syndrome, – metabolic acidosis, – pheochromocytoma (without the simultaneous use of alpha blockers), – simultaneous reception of monoamine oxidase inhibitors (MAO) (except of inhibitors MAO-B), – the age of 18 years (effectiveness and safety have not been established), – lactose intolerance, lactase deficiency or glucose-galactose syndrome malabsorption.
Dosage
10 mg
Indications
– Arterial hypertension; – Ischemic heart disease: prevention of angina attacks; – Chronic heart failure.
pharmachologic effect
Pharmacological group:
Beta1-selective blocker ATC code S07AV07.
Pharmacological properties:
Bisoprolol – selective beta 1-blocker, without its own sympathomimetic activity, has no membrane stabilizing action. As with other beta 1-blocker mechanism of action in hypertension is unclear. However, it is known that bisoprolol reduces renin activity in blood plasma, reduces myocardial oxygen demand, slows the heart rate (HR). It has antihypertensive, antiarrhythmic and antianginal effects. Blocking in low doses of beta 1-adrenergic receptors of the heart, stimulated by catecholamines reduces the formation of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP), the current lowers intracellular calcium ions, inhibits all heart functions reduces atrioventricular (AV) conduction and excitability. When exceeding the therapeutic dose has beta2-adrenoceptor blocking effect. Total peripheral vascular resistance at the beginning of the drug in the first 24 hours, is increased (as a result of reciprocal increase in the activity of alpha-adrenoceptor stimulation and removal of beta-2 adrenergic receptor), after 1-3 days returned to the initial value, and long-term use – is reduced. The antihypertensive effect is associated with a decrease in cardiac output, sympathetic stimulation of peripheral vascular disease, decreased activity sympathoadrenal system (SAS) (important for patients with initial hypersecretion renin), restoration of the sensitivity in response to a decrease in blood pressure (BP) and the influence on the central nervous system . When hypertension effect develops after 2-5 days, stable operation is noted after 1-2 months. Antianginal effect due to a decrease in myocardial oxygen demand by reducing contractility and other functions of the myocardium, lengthening of diastole, improving myocardial perfusion. By increasing the end-diastolic pressure in the left ventricle and increased tensile ventricular muscle fibers may be increased oxygen demand, especially in patients with chronic heart failure (CHF). When applied in high therapeutic doses, unlike nonselective beta-blockers, it has a less pronounced effect on organs containing beta 2-adrenoreceptors (pancreas, skeletal muscles, smooth muscles of peripheral arteries, bronchial and uterine) and carbohydrate metabolism; It does not cause a delay of sodium ions in the body; atherogenic action expression is not different from that of propranolol.
Conditions of supply of pharmacies
Prescription.
Dosing and Administration
Bisoprolol drug is taken orally, in the morning on an empty stomach, once, not liquid, squeezed small amounts of liquid. Tablets should not be chewed or triturate. Treatment of hypertension and angina in all cases receive mode and dosage selects the physician for each patient individually, in particular, taking into account heart rate and therapeutic response. When hypertension and coronary heart disease usually starting dose is 5 mg 1 time per day. If necessary to increase the dose of 10 mg 1 time per day. In the treatment of hypertension and angina maximum daily dose is 20 mg 1 time / day. Possible division of the daily dose into 2 doses. Treatment of stable chronic heart failure CHF Standard treatment regimen includes the use of inhibitors of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor antagonists II (in case of intolerance to ACE inhibitors), beta-blockers, diuretics and, optionally, cardiac glycosides. Start treating heart failure drug bisoprolol requires a mandatory holding a special titration phase and regular medical supervision. A prerequisite for treatment with bisoprolol is stable chronic heart failure with no signs of aggravation. CHF drug bisoprolol treatment starts in accordance with the following scheme titration. This may require individual adaptation depending on how well patients tolerate the prescribed dose, t. E. The dose can be increased only if the previous dose was well tolerated. The recommended starting dose is 1.25 mg (1/2 for 2.5 mg tablets) once daily. Depending on individual tolerance dose should be gradually increased to 2.5 mg, 3.75 mg (1 and 1/2 tablet 2.5 mg), 7.5 mg (3 tablets 2.5 mg) and 10 mg of 1 once a day. Each subsequent increase in dose should be administered at least two weeks. If an increase in the dose of the drug is poorly tolerated by the patient, may reduce the dose. The maximum recommended dose of CHF is 10 mg bisoprolol formulation 1 time per day. During titration we recommend regular monitoring of blood pressure, heart rate and severity of heart failure symptoms. Worsening symptoms of heart failure may flow from the first day of the drug. If the patient does not tolerate the maximum recommended dose may gradually decrease the dose. During the titration phase, or after it can be a temporary worsening CHF flow, hypotension or bradycardia. In this case it is recommended first of all to carry out correction of drug doses of concomitant therapy. You may also need a temporary reduction in the dose of bisoprolol or its cancellation. After stabilization of the patient should be a re-titration of the dosage or further treatment. Special groups of patients Impaired renal or hepatic function: • If abnormal liver or renal function mild or moderate usually not required to adjust the dose. • When expressed renal impairment (creatinine clearance less than 20 mL / min.) And in patients with severe liver disease with a maximum daily dose of 10 mg. Increasing the dose in such patients should be administered with extreme caution. There are currently insufficient data regarding the use of bisoprolol drug in patients with CHF, conjugated with type 1 diabetes, severe renal impairment and / or liver, restrictive cardiomyopathy, congenital heart disease or heart disease valve with marked hemodynamic disturbances. to also still not enough data has been received with respect to patients with chronic heart failure with myocardial infarction within the last 3 months.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist